Iopofosine | CAS# 208986-26-9 | Biochemical

MedKoo Cat#: 578240 | Name: Iopofosine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iopofosine, also known as NM-404, is a phospholipid drug conjugate which targets delivery of iodine 131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. Iopofosine I-131 demonstrated tumoricidal capacity in preclinical HNC tumor models and the theranostic pairing with CLR 124 presents a promising new treatment approach for personalizing administration of iopofosine I-131. Note: Iopofosine that we listed here is not a radioiodinated compound.

Chemical Structure

Iopofosine

CAS#208986-26-9

Theoretical Analysis

MedKoo Cat#: 578240

Name: Iopofosine

CAS#: 208986-26-9

Chemical Formula: C29H53INO4P

Exact Mass: 637.2757

Molecular Weight: 637.62

Elemental Analysis: C, 54.63; H, 8.38; I, 19.90; N, 2.20; O, 10.04; P, 4.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CLR-1401; CLR 1401; CLR1401; NM-404; NM 404; NM404; Iopofosine;

IUPAC/Chemical Name

Ethanaminium, 2-((hydroxy((18-(4-iodophenyl)octadecyl)oxy)phosphinyl)oxy)-N,N,N-trimethyl-, inner salt

InChi Key

ZOAIEFWMQLYMTF-UHFFFAOYSA-N

InChi Code

InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3

SMILES Code

C[N+](C)(C)CCOP(=O)([O-])OCCCCCCCCCCCCCCCCCCc1ccc(I)cc1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 637.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Marsh IR, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam DP, Hernandez R, Weichert JP, Harari PM, Bednarz BP. Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry. Cancer Biother Radiopharm. 2023 Sep;38(7):458-467. doi: 10.1089/cbr.2022.0084. Epub 2023 Apr 5. PMID: 37022739; PMCID: PMC10516227. 2: Schroeder HW, Hall LT. Molecular Imaging of Brain Metastases with PET. In: Sergi CM, editor. Metastasis [Internet]. Brisbane (AU): Exon Publications; 2022 May 3. Chapter 1. PMID: 35679455. 3: Neira S, Gago-Arias A, Gónzalez-Crespo I, Guiu-Souto J, Pardo-Montero J. Development of a Compartmental Pharmacokinetic Model for Molecular Radiotherapy with 131I-CLR1404. Pharmaceutics. 2021 Sep 17;13(9):1497. doi: 10.3390/pharmaceutics13091497. PMID: 34575575; PMCID: PMC8465706. 4: Neira S, Gago-Arias A, Guiu-Souto J, Pardo-Montero J. A kinetic model of continuous radiation damage to populations of cells: comparison to the LQ model and application to molecular radiotherapy. Phys Med Biol. 2020 Dec 10;65(24):245015. doi: 10.1088/1361-6560/aba21d. PMID: 32615551. 5: Hall LT, Titz B, Baidya N, van der Kolk AG, Robins HI, Otto M, Perlman SB, Weichert JP, Kuo JS. [124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors. Mol Imaging Biol. 2020 Apr;22(2):434-443. doi: 10.1007/s11307-019-01362-1. PMID: 31183841; PMCID: PMC7485611. 6: Marsh IR, Grudzinski J, Baiu DC, Besemer A, Hernandez R, Jeffery JJ, Weichert JP, Otto M, Bednarz BP. Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models. J Nucl Med. 2019 Oct;60(10):1414-1420. doi: 10.2967/jnumed.118.225409. Epub 2019 Mar 29. PMID: 30926646; PMCID: PMC6785791. 7: Besemer AE, Grudzinski JJ, Weichert JP, Hall LT, Bednarz BP. Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient. Cancer Biother Radiopharm. 2019 Feb;34(1):13-23. doi: 10.1089/cbr.2018.2568. Epub 2018 Oct 23. PMID: 30351218; PMCID: PMC6383576. 8: Grudzinski J, Marsh I, Titz B, Jeffery J, Longino M, Kozak K, Lange K, Larrabee J, Weichmann A, Moser A, Bednarz B. CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast Cancer. Cancer Biother Radiopharm. 2018 Apr;33(3):87-95. doi: 10.1089/cbr.2017.2376. PMID: 29641256; PMCID: PMC5905872. 9: Hall LT, Titz B, Robins HI, Bednarz BP, Perlman SB, Weichert JP, Kuo JS. PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors. Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):157-166. PMID: 28913154; PMCID: PMC5596318. 10: Baiu DC, Marsh IR, Boruch AE, Shahi A, Bhattacharya S, Jeffery JJ, Zhao Q, Hall LT, Weichert JP, Bednarz BP, Otto M. Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog. J Nucl Med. 2018 Feb;59(2):244-250. doi: 10.2967/jnumed.117.193748. Epub 2017 Jul 26. PMID: 28747518; PMCID: PMC5807534. 11: Besemer AE, Titz B, Grudzinski JJ, Weichert JP, Kuo JS, Robins HI, Hall LT, Bednarz BP. Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404. Phys Med Biol. 2017 Jul 6;62(15):6008-6025. doi: 10.1088/1361-6560/aa716d. PMID: 28682793; PMCID: PMC6771923. 12: Clark PA, Al-Ahmad AJ, Qian T, Zhang RR, Wilson HK, Weichert JP, Palecek SP, Kuo JS, Shusta EV. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood- Brain Barrier Model. Mol Pharm. 2016 Sep 6;13(9):3341-9. doi: 10.1021/acs.molpharmaceut.6b00441. Epub 2016 Aug 4. PMID: 27421304; PMCID: PMC5014630. 13: Marino R, Baiu DC, Bhattacharya S, Titz B, Hebron E, Menapace BD, Singhal S, Eickhoff JC, Asimakopoulos F, Weichert JP, Otto M. Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma. Am J Cancer Res. 2015 Oct 15;5(11):3422-35. PMID: 26807322; PMCID: PMC4697688. 14: Lubner SJ, Mullvain J, Perlman S, Pishvaian M, Mortimer J, Oliver K, Heideman J, Hall L, Weichert J, Liu G. A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies. Cancer Invest. 2015;33(10):483-9. doi: 10.3109/07357907.2015.1081691. Epub 2015 Nov 4. PMID: 26536061. 15: Morris ZS, Weichert JP, Saker J, Armstrong EA, Besemer A, Bednarz B, Kimple RJ, Harari PM. Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems. Radiother Oncol. 2015 Sep;116(3):504-9. doi: 10.1016/j.radonc.2015.06.015. Epub 2015 Jun 26. PMID: 26123834; PMCID: PMC4609259. 16: Grudzinski JJ, Titz B, Kozak K, Clarke W, Allen E, Trembath L, Stabin M, Marshall J, Cho SY, Wong TZ, Mortimer J, Weichert JP. A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. PLoS One. 2014 Nov 17;9(11):e111652. doi: 10.1371/journal.pone.0111652. PMID: 25402488; PMCID: PMC4234270. 17: Deming DA, Maher ME, Leystra AA, Grudzinski JP, Clipson L, Albrecht DM, Washington MK, Matkowskyj KA, Hall LT, Lubner SJ, Weichert JP, Halberg RB. Phospholipid ether analogs for the detection of colorectal tumors. PLoS One. 2014 Oct 6;9(10):e109668. doi: 10.1371/journal.pone.0109668. PMID: 25286226; PMCID: PMC4186834. 18: Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, Pazoles CJ, Pickhardt PJ, Kuo JS. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014 Jun 11;6(240):240ra75. doi: 10.1126/scitranslmed.3007646. PMID: 24920661; PMCID: PMC4336181. 19: Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M, Clipson L, Albrecht D, Bacher J, Washington MK, Weichert J, Halberg RB. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene. 2014 Apr 24;33(17):2245-54. doi: 10.1038/onc.2013.167. Epub 2013 May 27. PMID: 23708654; PMCID: PMC3883937. 20: Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan R, Washington MK, Torrealba JR, Weichert JP, Halberg RB. Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23. PMID: 22525701; PMCID: PMC3645915.